Final Results of Dendreon's phase III IMPACT Trial of Provenge

Dendreon Corporation (Nasdaq: DNDN) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

Those interested may access the call with the following information:

  Time:     9:00 AM ET/6:00 AM PT
  Date:     April 14, 2009
  Dial-in:  1-877-419-6594 (domestic) or +1-719-325-4855 (international)
  Webcast:  www.dendreon.com (homepage and investor relations section

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 888-203-1112 or 719-457-0820 for international callers; the conference ID number is 8182435. The replay will be available from 12:00 pm ET on April 14, 2009 until midnight ET on April 16, 2009.

In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.